Haemonetics (HAE) Competitors $55.48 -20.29 (-26.77%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$55.94 +0.46 (+0.83%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HAE vs. DXCM, HQY, LNTH, PODD, QTRX, SIBN, PEN, ZBH, MMSI, and ICUIShould you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), Quanterix (QTRX), SiBone (SIBN), Penumbra (PEN), Zimmer Biomet (ZBH), Merit Medical Systems (MMSI), and ICU Medical (ICUI). These companies are all part of the "medical" sector. Haemonetics vs. Its Competitors DexCom HealthEquity Lantheus Insulet Quanterix SiBone Penumbra Zimmer Biomet Merit Medical Systems ICU Medical DexCom (NASDAQ:DXCM) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations. Which has more volatility & risk, DXCM or HAE? DexCom has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Which has better valuation and earnings, DXCM or HAE? DexCom has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDexCom$4.30B6.97$576.20M$1.4453.06Haemonetics$1.36B1.96$167.68M$3.3116.76 Do insiders and institutionals have more ownership in DXCM or HAE? 97.8% of DexCom shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 0.3% of DexCom shares are owned by company insiders. Comparatively, 1.8% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer DXCM or HAE? In the previous week, DexCom had 32 more articles in the media than Haemonetics. MarketBeat recorded 49 mentions for DexCom and 17 mentions for Haemonetics. DexCom's average media sentiment score of 0.97 beat Haemonetics' score of 0.86 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 25 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Haemonetics 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer DXCM or HAE? DexCom presently has a consensus target price of $99.89, suggesting a potential upside of 30.75%. Haemonetics has a consensus target price of $95.70, suggesting a potential upside of 72.48%. Given Haemonetics' stronger consensus rating and higher possible upside, analysts plainly believe Haemonetics is more favorable than DexCom.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DexCom 0 Sell rating(s) 4 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.95Haemonetics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00 Is DXCM or HAE more profitable? DexCom has a net margin of 13.29% compared to Haemonetics' net margin of 12.32%. DexCom's return on equity of 30.41% beat Haemonetics' return on equity.Company Net Margins Return on Equity Return on Assets DexCom13.29% 30.41% 10.08% Haemonetics 12.32%26.37%9.22% SummaryDexCom beats Haemonetics on 12 of the 17 factors compared between the two stocks. Get Haemonetics News Delivered to You Automatically Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HAE vs. The Competition Export to ExcelMetricHaemoneticsMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$3.64B$10.34B$5.48B$20.70BDividend YieldN/A2.02%3.99%3.67%P/E Ratio16.7619.2529.8728.65Price / Sales1.9623.11422.9357.34Price / Cash10.5121.8135.9423.59Price / Book3.402.848.104.32Net Income$167.68M$211.77M$3.26B$995.66M7 Day Performance-25.73%1.54%0.64%1.91%1 Month Performance-27.13%2.31%2.42%-0.54%1 Year Performance-27.40%-11.48%27.60%14.76% Haemonetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HAEHaemonetics4.8525 of 5 stars$55.49-26.8%$95.70+72.5%-35.2%$3.64B$1.36B16.763,023Trending NewsEarnings ReportAnalyst ForecastGap DownHigh Trading VolumeDXCMDexCom4.9683 of 5 stars$89.53+0.6%$98.72+10.3%+10.2%$34.89B$4.03B66.8110,300HQYHealthEquity3.7437 of 5 stars$95.76-0.3%$118.55+23.8%+31.8%$8.31B$1.24B69.903,120Positive NewsLNTHLantheus4.6129 of 5 stars$72.41-0.7%$131.20+81.2%-42.9%$5.05B$1.53B20.57700Trending NewsEarnings ReportAnalyst ForecastGap UpPODDInsulet4.2325 of 5 stars$292.27+0.7%$321.00+9.8%+59.4%$20.42B$2.07B52.573,900Trending NewsEarnings ReportAnalyst ForecastGap UpQTRXQuanterix2.178 of 5 stars$6.49+10.9%$13.50+108.0%-56.3%$292.23M$137.42M-4.99460SIBNSiBone4.0444 of 5 stars$17.60+2.0%$22.50+27.8%+15.6%$735.10M$167.18M-27.50350Positive NewsEarnings ReportAnalyst ForecastPENPenumbra4.882 of 5 stars$229.90-1.4%$305.07+32.7%+46.7%$9.03B$1.19B216.894,500ZBHZimmer Biomet4.6468 of 5 stars$95.94-1.7%$111.39+16.1%-7.1%$19.30B$7.68B21.2317,000Positive NewsEarnings ReportAnalyst ForecastGap UpMMSIMerit Medical Systems4.1867 of 5 stars$84.46-0.3%$109.11+29.2%-3.4%$5.01B$1.36B41.407,400ICUIICU Medical4.6629 of 5 stars$127.50-1.8%$192.67+51.1%+6.7%$3.20B$2.38B-33.2915,000News CoveragePositive NewsEarnings Report Related Companies and Tools Related Companies DexCom Alternatives HealthEquity Alternatives Lantheus Alternatives Insulet Alternatives Quanterix Alternatives SiBone Alternatives Penumbra Alternatives Zimmer Biomet Alternatives Merit Medical Systems Alternatives ICU Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HAE) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
